KLK1 and inflammatory bowel disease: Our findings support human translational relevance, with KLK1 levels being reduced in IBD patients with UC and further reduced in patients with colorectal low‐grade endothelial neoplasia and colon cancer, suggesting KLK1 dysregulation in IBD and potential opportunities for intervention using KLK1.